A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13.


Journal Article

PURPOSE: The optimal cytotoxic regimens have not been established for patients with non-small cell lung cancer (NSCLC) who develop disease progression on first-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). Materials and Methods: We conducted a multi-center randomized phase II trial to compare the clinical outcomes between pemetrexed plus cisplatin combination therapy followed by maintenance pemetrexed (PC) and pemetrexed monotherapy (P) after failure of first-line EGFR-TKI. The primary objective was progression-free survival (PFS), and secondary objectives included overall response rate (ORR), overall survival (OS), health-related quality of life (HRQOL), and safety and toxicity profiles. RESULTS: A total of 96 patientswere randomized, and 91 patientswere treated at 14 centers in Korea. The ORR was 34.8% (16/46) for the PC arm and 17.8% (8/45) for the P arm (p=0.066). With 23.4 months of follow-up, the median PFS was 5.4 months in the PC arm and 6.4 months in the P arm (p=0.114). The median OS was 17.9 months and 15.7 months in PC and P arms, respectively (p=0.787). Adverse events ≥ grade 3 were reported in 12 patients (26.1%) in the PC arm and nine patients (20.0%) in the P arm (p=0.491). The overall time trends of HRQOL were not significantly different between the two arms. CONCLUSION: The outcomes of pemetrexed therapy in NSCLC patients with disease progression after firstline EGFR-TKI might not be improved by adding cisplatin.

Full Text

Duke Authors

Cited Authors

  • Yoo, KH; Lee, SJ; Cho, J; Lee, KH; Park, KU; Kim, KH; Cho, EK; Choi, YH; Kim, HR; Kim, H-G; Ahn, HJ; Lee, HY; Yun, HJ; Kang, J-H; Jeong, J; Choi, MY; Jung, S-H; Sun, J-M; Lee, S-H; Ahn, JS; Park, K; Ahn, M-J

Published Date

  • April 2019

Published In

Volume / Issue

  • 51 / 2

Start / End Page

  • 718 - 726

PubMed ID

  • 30177585

Pubmed Central ID

  • 30177585

Electronic International Standard Serial Number (EISSN)

  • 2005-9256

Digital Object Identifier (DOI)

  • 10.4143/crt.2018.324


  • eng

Conference Location

  • Korea (South)